Abemaciclib-Faslodex Combo Increases Progression-free Survival in Advanced Breast Cancer

Abemaciclib-Faslodex Combo Increases Progression-free Survival in Advanced Breast Cancer
Adding the CDK4/6 inhibitor abemaciclib to Faslodex (fulvestrant) is a promising way to treat patients with an advanced breast cancer who experienced a relapse or had their disease progress after endocrine therapy, clinical trial results indicate. The MONARCH Phase 3 trial covered patients with hormone receptor (HR)-positive, HER2-negative breast cancer. The combination therapy significantly improved patients' time to disease progression or death, compared with patients who received Faslodex plus a placebo, according to abemaciclib's maker, Lilly Oncology. "We are excited about the outcome of our first Phase 3 study for abemaciclib. These data are an important milestone in our goal of bringing abemaciclib to patients with advanced breast cancer, and we look forward to our upcoming conversations with regulators," Levi Garraway, MD, PhD, senior vice president of global development and medical affairs at Lilly Oncology, said in a news release. "This is another example of Lilly's commitment to delivering breakthrough treatments and improving outcomes for patients with cancer." Lilly is conducting several MONARCH trials in addition to the MONARCH Phase 3 study that has been completed. The global MONARCH 2 study (NCT02107703) is a randomized, double-blind, placebo-controlled trial. Its objective is to assess the safety and effectiveness of abemaciclib and Faslodex, versus a placebo and Faslodex, in patients with HR-p
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.